A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects
Part of paid clinical trials in Miami, Florida.
- Sponsor
- Corcept Therapeutics
- Study ID
- NCT06094738
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Accepted
Interventions
- Relacorilant under fasted conditions — DRUGOral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions
- Relacorilant after a high-fat meal — DRUGOral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal
- Relacorilant after a low-fat meal — DRUGOral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal
Study Details
The primary objective of the study is to evaluate the effects of a high-fat meal and of a low-fat meal on the bioavailability of relacorilant in healthy subjects.
Key Dates
- First listed
- Oct 23, 2023
- Start date
- Sep 19, 2020
- Status verified
- Oct 2023
- Primary completion
- Nov 16, 2020
- Completion
- Nov 16, 2020
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- OTHER
Arms
- Experimental: Relacorilant under fasted conditionsSubjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
- Experimental: Relacorilant after a high-fat mealSubjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
- Experimental: Relacorilant after a low-fat mealSubjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
Primary Outcome Measure
Area under the concentration-time curve from time zero to the last observed concentration of plasma relacorilant (AUC0-t) [ Time Frame: Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| inVentiv Health Clinical Research Services LLC | Miami | Florida | 33136 | - |
Find similar trials in Miami, FL
By research site
Related Studies
- Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated DonorsPHASE3 · Recruiting · Center for International Blood and Marrow Transplant Research · Boca Raton, Florida
- Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss OutcomeEnrolling By Invitation · Mayo Clinic · Jacksonville, Florida
- Breathing & Blood PressureRecruiting · Florida State University · Tallahassee, Florida
- A Study of Renal Microvessel Imaging for Chronic Kidney DiseasePHASE2 · Enrolling By Invitation · Mayo Clinic · Jacksonville, Florida